Introduction
The synthetic antimicrobial agent trimethoprim (Tp) selectively inhibits the bacterial enzyme dihydrofolate reductase (DHFR) (5,6,7,8-tetrahydrofolate : NADP' oxidoreductase, EC1.5.1.3) which catalyses the reduction of dihydrofolate to tetrahydrofolate, an essential cofactor involved in the biosynthesis of purines, pyrimidines and amino acids. Resistance to trimethoprim mediated by resistance plasmids (R-plasmids), was first reported by Fleming et al. ' The mechanism of resistance involves the plasmid-encoded synthesis of an additional trimethoprim-resistant dihydrofolate reductase which enables the inhibited host enzyme to be by-passed.
Seven major types of plasmid DHFRs present in gram-negative bacteria have been characterised on the basis of their biochemical properties (see re vie^).^ They vary in molecular size, heat lability, antifolate sensitivities and Michaelis Menten kinetics. Specific gene probes have now been developed which can identify several of the genes encoding the various enzyme types (see Materials and methods).
Strains producing each of the enzyme types I, 11, V, VI and VII exhibit a characteristically high level of resistance to trimethoprim-minimum inhibitory concentration (MIC) > 1000 mg/L. In contrast, strains producing the types I11 and IV plasmid DHFRs are only moderately resistant to trimethoprim (MIC < 64 mg/L). Unlike other plasmid DHFRs, the type I11 and IV enzymes are only slightly more resistant than the Escherichia coli chromosomal DHFR to the inhibitory action of trimethoprim (Ki = 19 nM and 63 nM respecti~ely).~. ' The gene encoding the prototype type I11 enzyme (now designated type IIIa) was found on a single plasmid (pAZ1) originating in a clinical isolate of Salmonella typhimurium in New Zealand in 1979.6 Two other biochemically similar plasmid-encoded enzymes (types IIIb and IIIc) have recently been reported in Shigella strains isolated in the USA.' The other moderately resistant DHFR gene, type IV, has been identified on several different plasmids, all of which originated in clinical isolates of bacteria in Southern India. ' In this paper we describe the identification of the type IIIa plasmid-encoded DHFR in bacteria isolated in Great Britain. This is the first report of the type IIIa trimethoprim resistant DHFR since its original discovery in New Zealand in 1979. 
Materials and methods

Bacterial strains and plasmids
MIC determination
The MIC of trimethoprim for E. coli strains was determined on Diagnostic Sensitivity Test Agar (DSTA ; Oxoid) as described previously.'
Hybridisation
Plasmid DNA was isolated on agarose gels and transferred to nitrocellulose filters with a Semidry Electroblotter (Sartorius Ltd) as described previously.'4 Hybridisation conditions were those of Carter et ul.,' with detection of a positive hybridisation result by means of a BlueGENE kit (Bethesda Research Laboratories Ltd); the conditions and protocols used were those recommended by the manufacturer.
Enzyme preparation and assay
DHFR was prepared from 2-L overnight cultures of bacteria grown in IsoSensitest Broth (Oxoid) with vigorous agitation at 37"C, as described by Young and Amyes.' The cells were harvested by centrifugation (6000 g, 10 min, 15OC) and re-suspended in buffer A (50 mM sodium phosphate, pH 7.4, containing 10 mM pmercaptoethanol and 1 mM EDTA). The bacteria were disrupted by sonication and the cell debris was removed by centrifugation (40 000 g, 1 h, 4°C). DHFR activity was assayed at 37°C in 40 mM sodium phosphate buffer, pH 6.0, as described previously.2 One unit of DHFR activity was defined as the amount of enzyme required to reduce 1 nmol of dihydrofolatelmin. Ammonium sulphate was added to 50% saturation. After centrifugation (14 000 g, 30 min, 4"C), further ammonium sulphate was added to the supernate to give 80% saturation and, following further centrifugation, the pellet was dialysed against buffer A. It was applied to a Sephadex G-75 column (2 cm2 x 90 cm) previously equilibrated with buffer A and eluted with the same buffer. Molecular mass was determined by Sephadex exclusion chromatography as described previously.2 Heat sensitivity, enzyme kinetics and inhibitor studies were performed as previously described.16
Iso-electric focusing of DHFRs
Iso-electric focusing was performed by a modification of the method of Broad and Smith;" 10-pl volumes of the re-suspended and dialysed 80% saturation ammonium sulphate pellet were applied to the surface of standard LKB polyacrylamide plates containing ampholines capable of producing a gradient from pH 3-5 to 9.5 (no. 1804-101). Standard PI markers were also applied to each gel. Samples were focused for 6 h on a cooled (9°C) LKB Ultrophor electrophoresis system (no. 2217) at 500 V and 20 mA, limited by constant power at 1 W. The gels were stained for DHFR activity by the method of Broad and Smith. l 7
Results
Identijication and cloning of the type IIIa DHFR gene E. coli TM858 was isolated from the urine of a hospitalised patient in Nottinghamshire in 1980. This strain was highly resistant to trimethoprim (MIC > 1024 mg/L). Trimethoprim resistance was not freely transferable and could be mobilised to E. coli K 12 strain 553-2 only following transposition on to plasmid RP4. The resulting transconjugant, E. coli 553-2 (pUN635 = RP4 : : Tn317.9, was also highly resistant to trimethoprim (MIC > 1024 mg/ L). Therefore, purified plasmid DNA was hybridised with those gene probes known to identify high level trimethoprim resistance genes (i.e., DHFR types I, I1 and V gene probes). However no hybridisation occurred with any of these probes, which indicated the presence of a novel DHFR gene.
To expedite a more detailed analysis of the trimethoprim resistance gene and its product, the trimethoprim resistance gene of strain 553-2 (pUN635) was cloned into the vector plasmid Pur$cation of the DHFR encoded by pUN972 DHFR activity was purified from 2 L of culture. After removal of nucleic acids with streptomycin sulphate, the protein was selectively precipitated with ammonium sulphate between 50 and 80% saturation. The precipitated protein was dialysed against buffer A and applied to a pre-calibrated Sephadex G-75 column. A major DHFR peak was eluted during gel filtration corresponding to a molecular weight of 17 000 daltons ( fig. 2) . This is indistinguishable from the 16 900 daltons reported for the original type IIIa enzyme encoded by plasmid pAZ 1.
Characterisation of thepUN972 andpAZI encoded DHFRs
Inhibitor pro3les. To compare the pUN972-encoded enzyme with the original type IIIa enzyme, the DHFR encoded by pAZl was also purified and separated by gel filtration of Sephadex G-75. Fractions containing peak DHFR activity were pooled for each enzyme preparation and used for comparative c haracterisat ion.
Both enzymes were found to be heat stable, they retained more than 50% activity after being held at 45°C for 12 min. Partially purified DHFR activity was assayed in the presence of increasing concentrations of trimethoprim and methotrexate. Both enzymes were approximately 10 times more resistant to inhibition by trimethoprim than the E. coli chromosomal DHFR, losing 50% of their activity in the presence of 4.5 PM trimethoprim. This is also similar to the value previously reported by Joyner et aL4 for the pAZ1-encoded enzyme. Similarly, both enzymes were inhibited by 50% in the presence of 10 times greater concentrations of methotrexate ( 0 . 0 2~~) than that required to inhibit the E. coli chromosomal enzyme.
Michaelis Menten kinetics. The activity of the pUN972 encoded enzyme was investigated in conditions of partial saturation with dihydrofolate and the results were analysed by the method of Lineweaver and Burk ( fig. 3) . The results ( fig. 3) A show that the K m value for dihydrofolate was 0.41 PM, a value similar to that previously published for the pAZl encoded enzyme. When the assays were repeated in the presence of trimethoprim it was found that the maximum velocity remained the same ( fig. 3) , indicating that the drug causes competitive inhibition of the enzyme. The inhibitor constant (Ki) for trimethoprim was 0.04 PM, again similar to that reported for the pAZl-encoded, type IIIa DHFR. Zso-electric focusing. Final evidence indicating that the pUN972-encoded dihydrofolate reductase was identical to the type IIIa enzyme encoded by pAZl was obtained by determination of the isoelectric point of the two enzymes. When run concurrently, both enzymes were found to co-focus with a PI of 6.1, thus confirming the classification of the pUN972-encoded enzyme as a type IIIa DHFR( fig.4 ).
Discussion
The original strain of E. coli studied in this paper exhibited high level resistance to trimethoprim, characteristic of plasmid DHFR types I, 11, V, VI and VII. However, hybridisation studies employing the available DNA probes specific for these DHFR gene types failed to identify a previously characterised DHFR gene. Further genetic analysis, involving cloning of the trimethoprim resistance gene into the vector plasmid pUC18, revealed a DHFR gene conferring only a moderate level of trimethoprim resistance in the recombinant strain. Detailed biochemical analysis of the enzyme product of this gene showed it to be identical with the type IIIa enzyme, encoded by pAZ1, described by Fling et aZe6 This is the first report of the type IIIa DHFR gene since its original detection in a clinical isolate in New Zealand.
One interesting feature of this work is the apparent reduction in MIC of trimethoprim for the strain carrying the cloned type IIIa DHFR compared to the original isolate. One possible explanation is that a second DHFR gene, conferring a high level of resistance, was present on the original transposon and that this "masked" the presence of the low level type IIIa determinant ; however, other more complicated scenarios involving gene copy numbers or gene regulation are perhaps more feasible. For example, the MIC could vary depending on the orientation of the insert and whether the gene was utilising its own promotors or those of pUC18.
An important consequence of this study has been the production of a new type IIIa DHFR gene probe. The previously available 855-bp DNA probe for the type IIIa gene contains approximately 350 bp extraneous to the structural gene;18 consequently it has been shown to produce occasional "false positive" hybridisation reactions (K. J. Towner, unpublished results). The gene probe constructed in this study is smaller (700 bp) and may prove, therefore, to be more specific. The elaborate techniques involved in the detection and confirmation of the type IIIa DHFR gene suggest that the apparent low incidence of the type IIIa enzyme may result from a lack of detection rather than a scarcity of the gene. Therefore, the new gene probe constructed in this study may be very useful in clarifying the epidemiology of what has previously been considered to be an extremely unusual resistance gene.
